$EVOK
Evoke Pharma Inc

2014 Q4 Form 10-Q Financial Statement

#000156459014005646 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $740.0K $730.0K $940.0K
YoY Change -21.28% 78.05% 176.47%
% of Gross Profit
Research & Development $2.176M $3.088M $636.4K
YoY Change 241.97% 3822.69% 99.91%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.176M $3.821M $636.4K
YoY Change 241.97% 686.91% 99.91%
Operating Profit -$3.821M
YoY Change 686.91%
Interest Expense -$10.00K $5.906K -$40.00K
YoY Change -75.0% -114.77% 300.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$4.181K $0.00
YoY Change 1244.37%
Pretax Income -$2.920M -$3.830M -$1.620M
YoY Change 80.25% 681.63% 141.79%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.920M -$3.825M -$1.617M
YoY Change 80.6% 687.27% 140.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$482.6K -$633.1K -$269.6K
COMMON SHARES
Basic Shares Outstanding 6.112M 6.100M shares 6.097M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.16M $12.18M $24.20M
YoY Change -41.49% -48.69%
Cash & Equivalents $14.16M $12.18M $24.20M
Short-Term Investments
Other Short-Term Assets $161.4K $1.130M $230.0K
YoY Change -29.81%
Inventory
Prepaid Expenses $931.5K $1.132M $234.3K
Receivables
Other Receivables
Total Short-Term Assets $15.25M $13.31M $24.43M
YoY Change -37.58% -43.94% 20958.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.02K $82.55K $555.5K
YoY Change -90.45%
Total Long-Term Assets $53.02K $82.55K $555.5K
YoY Change -90.45%
TOTAL ASSETS
Total Short-Term Assets $15.25M $13.31M $24.43M
Total Long-Term Assets $53.02K $82.55K $555.5K
Total Assets $15.30M $13.39M $24.99M
YoY Change -38.76% -43.59% 21437.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.010M $1.050M $280.0K
YoY Change 260.71% -11.02%
Accrued Expenses $700.0K $640.0K $560.0K
YoY Change 25.0% 64.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $126.8K $0.00 $1.443M
YoY Change -91.21% -100.0%
Total Short-Term Liabilities $1.848M $1.685M $2.285M
YoY Change -19.12% -36.08% 300.57%
LONG-TERM LIABILITIES
Long-Term Debt $4.196M $0.00 $1.511M
YoY Change 177.64% -100.0% 54.26%
Other Long-Term Liabilities $10.00K $6.830K
YoY Change
Total Long-Term Liabilities $4.196M $10.00K $1.518M
YoY Change 176.39% -99.47% 54.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.848M $1.685M $2.285M
Total Long-Term Liabilities $4.196M $10.00K $1.518M
Total Liabilities $6.044M $1.700M $3.803M
YoY Change 58.93% -62.35% 145.34%
SHAREHOLDERS EQUITY
Retained Earnings -$35.94M -$33.02M -$22.69M
YoY Change 58.38%
Common Stock $45.13M $611.00 $43.87M
YoY Change 2.86% 5.71% 35382745.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.189M $11.69M $21.18M
YoY Change
Total Liabilities & Shareholders Equity $15.23M $13.39M $24.99M
YoY Change -39.03% -43.59% 21437.64%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$2.920M -$3.825M -$1.617M
YoY Change 80.6% 687.27% 140.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.520M -$3.910M -$1.890M
YoY Change 33.33% 1348.15% 190.77%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.500M 40.00K 2.350M
YoY Change 91.49% -99.83%
NET CHANGE
Cash From Operating Activities -2.520M -3.910M -1.890M
Cash From Investing Activities
Cash From Financing Activities 4.500M 40.00K 2.350M
Net Change In Cash 1.980M -3.870M 460.0K
YoY Change 330.43% -117.06% -170.77%
FREE CASH FLOW
Cash From Operating Activities -$2.520M -$3.910M -$1.890M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
284915
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1131685
CY2013Q4 us-gaap Assets Current
AssetsCurrent
24430953
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12176682
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234262
CY2014Q3 us-gaap Liabilities
Liabilities
1700181
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6112091
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2284906
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
611
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24196691
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
636098
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
557399
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
555505
CY2014Q3 us-gaap Assets
Assets
13390920
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1685467
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3821173
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
3821173
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
732800
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q4 us-gaap Assets
Assets
24986458
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8980199
us-gaap Operating Income Loss
OperatingIncomeLoss
-1021047
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6054250
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1190212
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22691468
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
700489
us-gaap Operating Expenses
OperatingExpenses
1021047
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-311
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-92245
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3825354
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33019346
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13390920
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
105625
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4181
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-485593
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6112091
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2420167
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6112091
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
485593
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-39000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10235633
us-gaap Operating Expenses
OperatingExpenses
10235633
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-485904
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1049369
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1442592
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6096752
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6096752
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24986458
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1511461
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
610
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-44562
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
843153
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
406862
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25200000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12020009
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116013
CY2013Q4 us-gaap Liabilities
Liabilities
3803197
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
71875
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
49375
CY2013Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
101875
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-198720
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42875
us-gaap Net Income Loss
NetIncomeLoss
-1219767
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6028309
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1153751
us-gaap Share Based Compensation
ShareBasedCompensation
13881
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3039810
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24773042
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23622040
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23738053
us-gaap Interest Paid
InterestPaid
58790
us-gaap Interest Paid
InterestPaid
94750
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.71
us-gaap Share Based Compensation
ShareBasedCompensation
792481
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-7884
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3088373
CY2014Q3 us-gaap Interest Income Other
InterestIncomeOther
1725
CY2014Q3 us-gaap Assets Current
AssetsCurrent
13308367
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82553
CY2014Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
14714
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6830
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44709474
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43874119
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
11690739
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
21183261
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78731
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7815466
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
320558
CY2013Q3 us-gaap Interest Income Other
InterestIncomeOther
629
us-gaap Interest Income Other
InterestIncomeOther
8995
us-gaap Interest Income Other
InterestIncomeOther
2850
CY2014Q3 us-gaap Interest Expense Other
InterestExpenseOther
5906
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
2000000
CY2013Q3 us-gaap Interest Expense Other
InterestExpenseOther
39940
us-gaap Interest Expense Other
InterestExpenseOther
101240
us-gaap Interest Expense Other
InterestExpenseOther
119570
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
82000
us-gaap Net Income Loss
NetIncomeLoss
-10327878
us-gaap Other Noncash Expense
OtherNoncashExpense
54076
us-gaap Other Noncash Expense
OtherNoncashExpense
17446
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
349915
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1151002
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
3000000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
82685
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
2426958
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
49000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
782661
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
337250
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
782661
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
337250
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
303961
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
7629
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D

Files In Submission

Name View Source Status
0001564590-14-005646-index-headers.html Edgar Link pending
0001564590-14-005646-index.html Edgar Link pending
0001564590-14-005646.txt Edgar Link pending
0001564590-14-005646-xbrl.zip Edgar Link pending
evok-10q_20140930.htm Edgar Link pending
evok-20140930.xml Edgar Link completed
evok-20140930.xsd Edgar Link pending
evok-20140930_cal.xml Edgar Link unprocessable
evok-20140930_def.xml Edgar Link unprocessable
evok-20140930_lab.xml Edgar Link unprocessable
evok-20140930_pre.xml Edgar Link unprocessable
evok-ex311_201409306.htm Edgar Link pending
evok-ex312_201409307.htm Edgar Link pending
evok-ex321_201409308.htm Edgar Link pending
evok-ex322_201409309.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending